| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 213 | 237 | 249 | 250 | 248 | 287 | 284 | 264 | 267 | 324 | 334 | 297 | 382 | 374 | 349 | 401 | 396 | 405 | 412 | 429 | 417 | 478 | 461 | 462 | 425 | 432 | 404 |
| Expenses | 206 | 224 | 238 | 224 | 230 | 260 | 255 | 239 | 227 | 268 | 272 | 250 | 300 | 300 | 285 | 329 | 337 | 345 | 337 | 363 | 365 | 410 | 405 | 401 | 384 | 392 | 399 |
| EBITDA | 7 | 13 | 11 | 26 | 18 | 27 | 30 | 25 | 40 | 56 | 62 | 47 | 82 | 74 | 65 | 72 | 60 | 60 | 74 | 66 | 52 | 68 | 56 | 61 | 42 | 40 | 6 |
| Operating Profit % | 3 % | 5 % | 4 % | 9 % | 7 % | 9 % | 10 % | 9 % | 15 % | 17 % | 18 % | 15 % | 21 % | 19 % | 18 % | 18 % | 15 % | 15 % | 18 % | 15 % | 12 % | 13 % | 12 % | 9 % | 10 % | 9 % | 1 % |
| Depreciation | 17 | 18 | 18 | 20 | 17 | 18 | 18 | 18 | 19 | 19 | 17 | 19 | 22 | 20 | 19 | 18 | 20 | 16 | 17 | 18 | 20 | 21 | 24 | 26 | 28 | 29 | 29 |
| Interest | 7 | 5 | 4 | 5 | 6 | 5 | 7 | 8 | 6 | 6 | 6 | 5 | 4 | 3 | 4 | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 10 | 12 | 14 | 18 | 16 |
| Profit Before Tax | -12 | -10 | 4 | 9 | -0 | 10 | 11 | 8 | 24 | 37 | 38 | 34 | 61 | 65 | 51 | 60 | 48 | 67 | 38 | 39 | 34 | 46 | 23 | 33 | 7 | -5 | -31 |
| Tax | 0 | -3 | -1 | -2 | -2 | 2 | 2 | 2 | 7 | 11 | 12 | 9 | 22 | 23 | 18 | 19 | 10 | 18 | 10 | 13 | 10 | 11 | 7 | 11 | 5 | 5 | -3 |
| Net Profit | -12 | -7 | 5 | 12 | 2 | 8 | 9 | 5 | 17 | 26 | 25 | 25 | 40 | 42 | 33 | 41 | 39 | 50 | 28 | 26 | 24 | 35 | 16 | 22 | 2 | -10 | -28 |
| EPS in ₹ | -1.32 | -0.81 | 0.57 | 1.25 | 0.20 | 0.85 | 0.99 | 0.58 | 1.85 | 2.78 | 2.75 | 2.71 | 4.30 | 4.52 | 3.58 | 4.39 | 4.19 | 5.40 | 3.05 | 2.80 | 2.62 | 3.82 | 1.69 | 2.39 | 0.20 | -1.09 | -3.08 |
Indoco Remedies
223.54
-0.67
(-0.30%)
Market Cap
2,060.64 Cr
EPS
10.53
PE Ratio
126.00
Dividend Yield
0.67 %
Industry
Healthcare52 Week High
387.55
52 Week low
190.00
PB Ratio
1.90
Debt to Equity
0.47
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
Company News
View All News
Indoco Remedies' Anacipher Facility Completes FDA Inspection with One Form 4831 day ago
Indoco Remedies announced that its Anacipher facility has completed a U.S. Food and Drug Administration (FDA) inspection. At the conclusion of the inspection, the facility received one Form 483, which indicates that the FDA inspector observed conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Indoco Remedies: USFDA Completes Inspection of AnaCipher Facility1 day ago
USFDA conducted a 5-day inspection of Indoco Remedies' clinical research wing AnaCipher in Hyderabad, covering clinical and bioanalytical phases of three BA/BE studies. The facility received one Form 483, which the company will respond to within the deadline.
Indoco Remedies' Anacipher Facility Completes FDA Inspection with One Form 4831 day ago
Indoco Remedies announced that its Anacipher facility has completed a U.S. Food and Drug Administration (FDA) inspection. The inspection concluded with the facility receiving one Form 483, which typically indicates observations of potential violations of FDA regulations.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,666.20 | 3,99,777.19 | 33.68 | 49,887.20 | 12.06 | 9,648 | 13.77 | 47.46 | |
| 5,510.00 | 1,46,273.19 | 71.18 | 8,184.00 | 0.89 | 1,600 | 64.53 | 40.99 | |
| 1,443.10 | 1,16,546.78 | 23.41 | 26,520.70 | 14.17 | 4,155 | 47.38 | 48.78 | |
| 3,074.45 | 1,04,053.36 | 55.61 | 10,785.70 | 11.59 | 1,656 | 13.54 | 47.28 | |
| 1,099.00 | 91,701.76 | 17.35 | 28,905.40 | 12.36 | 5,578 | 1.69 | 31.30 | |
| 1,945.65 | 88,760.08 | 31.45 | 20,141.50 | 19.94 | 1,936 | 38.82 | 44.40 | |
| 2,143.00 | 88,413.09 | 44.67 | 10,615.60 | 19.57 | 1,942 | -16.38 | 33.38 | |
| 877.50 | 88,297.03 | 19.97 | 19,831.50 | 13.82 | 3,831 | 29.92 | 45.15 | |
| 29,969.35 | 63,682.78 | 48.58 | 6,097.20 | 10.80 | 1,201 | 16.01 | 58.42 | |
| 1,090.00 | 63,307.38 | 17.97 | 29,559.20 | 17.55 | 3,169 | -10.04 | 42.48 |
Growth Rate
Revenue Growth
9.35 %
Net Income Growth
-31.83 %
Cash Flow Change
-12.37 %
ROE
-36.80 %
ROCE
-35.79 %
EBITDA Margin (Avg.)
-19.41 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 |
| Fixed Assets | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 |
| Current Assets | 385 | 465 | 572 | 539 | 538 | 563 | 623 | 774 | 814 | 955 |
| Capital Work in Progress | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 |
| Investments | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 9 |
| Other Assets | 443 | 496 | 666 | 614 | 605 | 631 | 677 | 809 | 864 | 1,057 |
| Total Liabilities | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 |
| Current Liabilities | 262 | 303 | 390 | 417 | 446 | 459 | 407 | 425 | 425 | 612 |
| Non Current Liabilities | 65 | 61 | 155 | 146 | 152 | 133 | 139 | 157 | 205 | 422 |
| Total Equity | 519 | 577 | 651 | 675 | 661 | 680 | 769 | 905 | 1,028 | 1,111 |
| Reserve & Surplus | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,092 |
| Share Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 1 | -0 | 50 | -52 | 12 | 3 | -14 | 8 | -7 | 4 |
| Investing Activities | -88 | -111 | -171 | -135 | -104 | -56 | -67 | -121 | -208 | -433 |
| Operating Activities | 109 | 112 | 89 | 123 | 132 | 123 | 82 | 174 | 179 | 157 |
| Financing Activities | -20 | -2 | 132 | -39 | -16 | -64 | -30 | -44 | 23 | 280 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 58.69 % | 58.69 % | 58.69 % | 58.69 % | 58.69 % | 58.69 % | 58.69 % | 58.69 % | 58.69 % | 58.74 % | 58.74 % | 58.72 % | 58.75 % | 58.75 % | 58.80 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.12 % | 0.12 % | 1.59 % | 1.69 % | 1.91 % | 1.47 % | 1.70 % | 1.25 % |
| DIIs | 18.88 % | 18.80 % | 17.22 % | 17.23 % | 17.64 % | 17.52 % | 17.33 % | 18.07 % | 17.29 % | 17.78 % | 19.56 % | 19.41 % | 18.67 % | 18.24 % | 18.90 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 15.92 % | 15.92 % | 17.32 % | 17.87 % | 17.87 % | 17.23 % | 16.85 % | 16.74 % | 16.48 % | 16.84 % | 15.24 % | 15.33 % | 16.29 % | 16.30 % | 16.07 % |
| Others | 6.52 % | 6.59 % | 6.78 % | 6.21 % | 5.80 % | 6.57 % | 7.13 % | 6.39 % | 7.42 % | 5.04 % | 4.77 % | 4.62 % | 4.81 % | 5.01 % | 4.99 % |
| No of Share Holders | 21,508 | 24,518 | 34,746 | 37,279 | 37,863 | 38,498 | 38,072 | 35,713 | 34,731 | 36,588 | 32,600 | 33,201 | 34,511 | 34,416 | 34,676 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1.6 | 1 | 0.3 | 0.3 | 1.5 | 2.25 | 2.25 | 1.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.75 | 0.49 | 0.14 | 0.1 | 0.4 | 0.69 | 0.68 | 0.67 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
REVISED DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS2015 (LISTING REGULATIONS)
REVISED DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS2015 (LISTING REGULATIONS)
DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS2015 (LISTING REGULATIONS)
DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS2015 (LISTING REGULATIONS)
DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS2015 (LISTING REGULATIONS)
DISCLOSURE UNDER REGULATION 30 OF THE SEBI (LODR) REGULATIONS2015 (LISTING REGULATIONS)
SHOW CAUSENOTICE - ORDER OF DROPPED PROCEEDING
SHOW CAUSENOTICE - ORDER OF DROPPED PROCEEDING
Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
SHOW CAUSE NOTICE
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
SHOW CAUSE NOTICE
SHOW CAUSE NOTICE - ORDER OF DROPPED PROCEEDING
Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Announcement under Regulation 30 (LODR)-Credit Rating
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31St December 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 21St January 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended 31-12-2024
Change Of Name Of Registrar & Share Transfer Agent (RTA) Of The Company
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Closure of Trading Window
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015- Warning Letter From USFDA
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosure Regarding Show Cause Notice (SCN) U/S 73(1) In Form GST DRC - 01 Received From The Goods And Service Tax (GST) Authority
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Company Filings to Exchanges
Jan 2025
Technical Indicators
RSI(14)
Neutral 40.52
ATR(14)
Less Volatile 14.73
STOCH(9,6)
Neutral 73.37
STOCH RSI(14)
Overbought 92.47
MACD(12,26)
Bullish 2.59
ADX(14)
Strong Trend 26.27
UO(9)
Bearish 55.87
ROC(12)
Downtrend And Accelerating -6.83
WillR(14)
Neutral -43.87
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
